1. Home
  2. PNR vs GKOS Comparison

PNR vs GKOS Comparison

Compare PNR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pentair plc.

PNR

Pentair plc.

HOLD

Current Price

$64.21

Market Cap

8.8B

Sector

Industrials

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$180.54

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNR
GKOS
Founded
1966
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8B
9.7B
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
PNR
GKOS
Price
$64.21
$180.54
Analyst Decision
Buy
Strong Buy
Analyst Count
17
14
Target Price
$73.60
★ $199.31
AVG Volume (30 Days)
★ 2.6M
926.3K
Earning Date
10-27-2026
10-28-2026
Dividend Yield
★ 1.73%
N/A
EPS Growth
★ 5.88
N/A
EPS
★ 2.76
N/A
Revenue
N/A
★ $507,442,000.00
Revenue This Year
N/A
$36.30
Revenue Next Year
$18.49
$23.25
P/E Ratio
$59.30
★ N/A
Revenue Growth
N/A
★ 32.33
52 Week Low
$51.13
$80.91
52 Week High
$109.89
$191.62

Technical Indicators

Market Signals
Indicator
PNR
GKOS
Relative Strength Index (RSI) 79.63 65.62
Support Level $57.60 $175.04
Resistance Level $77.03 $184.68
Average True Range (ATR) 1.66 6.45
MACD 1.42 1.90
Stochastic Oscillator 91.46 80.18

Price Performance

Historical Comparison
PNR
GKOS

About PNR Pentair plc.

Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: